JP2012176916A - New resveratrol derivative - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a new resveratrol derivative, its production method, an anticancer agent containing the derivative, and others.SOLUTION: The new resveratrol derivative is expressed by formula (1). A pharmacologically allowable salt, ester or ether is also disclosed.

Description

  The present invention relates to a novel resveratrol derivative, a method for producing the novel resveratrol derivative, and an anticancer agent, α-glucosidase inhibitor, sugar absorption inhibitor, and diabetes preventive agent containing the novel resveratrol derivative. .

Breakthrough research results are being revealed for resveratrol, a stilbene derivative contained in grape skin. Resveratrol is a compound having an antibacterial action that originally exists as a phytoalexin that protects grapes from pathogenic bacteria and is known to be contained in grape skins regardless of whether they are red or white. Recent studies are revealing that resveratrol has a useful effect on mammals as well. The useful physiological effect of red wine called so-called “French paradox” is attributed to various physiologically active functions including the antioxidant ability of resveratrol. Furthermore, resveratrol is being clarified to be effective for many diseases (Non-patent Document 1), and one of them is reported that resveratrol has a strong anticancer activity (non-patent document 1). Patent Document 2).
In addition, as a derivative of resveratrol, a number of resveratrol polymers such as ε-viniferin (dimer), α-viniferin (trimer), and vaticanol C (tetramer) have been reported in nature. Has been. Although there is also a report on a non-natural type resveratrol derivative (for example, Patent Document 1), no example has been found in which the novel compound of the present invention is identified and the physiological activity is reported in detail.

  Caffeic acid is a precursor of functional components such as chlorogenic acid and rosmarinic acid, as well as a precursor of lignin and lignan, which are the main components of trees, and is a relatively abundant component in nature. A large amount of chlorogenic acid is contained in coffee beans and the like and rosmarinic acid is contained in Lamiaceae plants. Moreover, caffeic acid is contained in the fruits and peels of many fruits. There are disclosures of the usefulness of caffeic acid and useful caffeic acid derivatives, for example, an antihypertensive agent for hypertension consisting of caffeic acid and ferulic acid (Patent Document 2), an autonomic nervous function improving agent containing caffeic acid as an active ingredient ( Patent Document 3), Vascular Endothelial Function Improvement Agent with Caffeic Acid as Active Component (Patent Document 4), Blood Fluidity Improvement Agent with Caffeic Acid as Active Component (Patent Document 5), Cerebral Fatigue with Caffeic Acid as Active Component A recovery agent (Patent Document 6) and a secondary bile acid lowering agent (Patent Document 7) containing caffeic acid as an active ingredient are known.

  There is also prior art related to caffeic acid derivatives. For example, a composition for cosmetics or an external preparation for skin containing a caffeic acid amide derivative as an active ingredient (Patent Document 8), an antimicrobial agent containing a sugar transfer product of caffeic acid as an active ingredient (Patent Document 9), a caffeic acid derivative Neurite elongation agent (Patent Document 10) containing as an active ingredient, hemodynamic improving agent containing Serotoninamide of caffeic acid or its glycoside as an active ingredient (Patent Document 11), Alzheimer containing caffeoylquinic acid as an active ingredient Disease prevention or treatment agent (patent document 12), method for efficiently producing caffeic acid phenethyl ester which is a minor component in propolis (patent document 13), enzyme synthesis method of cinnamic acid derivative (patent document 14), 2- An anticancer agent containing a caffeic acid derivative such as caffeic acid cyclohexaester as an active ingredient (Patent Document 15), a novel polyphenol obtained by enzymatic synthesis using caffeic acid as one of the raw materials Lumpur compound (Patent Document 16) are known.

  Thus, resveratrol and caffeic acid are natural substances rich in food experience and are safe compounds with excellent bioregulatory functions. Therefore, there are many efforts for various derivatives.

  Since many of caffeic acid, resveratrol, and derivatives thereof exhibit excellent utility, technical disclosures for efficiently producing these as raw materials and lead compounds have been made. As described above, since many caffeic acids and caffeic acid derivatives exhibit excellent utility, a technical disclosure for efficiently producing caffeic acid as a raw material or a lead compound has been made. For example, a method for producing from coffee lees (patent document 17), a method for producing from burdock leaves (patent document 18), and a method for producing from sweet potato shochu distilled liquor (patent document 19) are known. In addition, with regard to resveratrol, efforts are being made to increase the resveratrol concentration in foods, and after increasing the resveratrol concentration by ultraviolet irradiation, a resveratrol-containing extract is obtained and the extract is used as a food. An added food has been proposed (Patent Document 20).

In recent years, lifestyle-related diseases resulting from changes in dietary habits have become a major problem. For example, the number of diabetic patients is increasing due to various factors such as excessive intake of sugar and fat and lack of exercise.
Diabetes, a lifestyle-related disease, is a disease in which the glucose concentration in the blood rises abnormally. According to the Ministry of Health, Labor and Welfare's 2007 National Health and Nutrition Survey, there are over 22.1 million diabetics and reserves. This is more than 20% of adults in Japan, and countermeasures are urgently needed. It is said that around 6% of adult population in the world or a reserve army has occurred, and the United Nations November 14th is “World Diabetes Day”, an exercise to raise awareness of its prevention, treatment and medical treatment. It is carried out.

  Diabetes is caused by depletion of insulin, a hormone that regulates blood sugar levels, a decrease in insulin secretion, and a decrease in insulin sensitivity. The causes are inheritance, obesity, stress, smoking and the like. As a characteristic symptom in diabetic patients and their reserve groups, a rapid increase in postprandial blood glucose level is observed. This occurs when the sugar contained in food is absorbed and the blood glucose level regulating function does not operate. One means for preventing this is an α-glucosidase inhibitor that moderates sugar absorption. α-Glucosidase inhibitors are popular drugs that are often used as first-line drugs for diabetes drug treatment.

  Not only medicinal products but also “special insurance foods” with a sugar absorption inhibitory function are approved and sold. There are also products with α-glucosidase inhibitory activity as the mechanism of action, and it is known that the components involved are often sugar analogs and coumarins (Patent Document 21).

According to a survey by the Ministry of Health, Labor and Welfare, 30% of Japanese deaths in 2008 are malignant neoplasms or cancer. While many cancers are leveling off or decreasing due to the development of medical technology and drugs, one of the increasing cancers is oral cancer, accounting for 5% of cancer occurrences. In 2015, the number of affected cases is expected to be four times the current number. In the current research, luteolin is known as a natural product-derived compound that can be ingested on a daily basis (Non-patent Document 3).
However, it is desired to develop a therapeutic or preventive agent for safe cancer, particularly oral cancer, which has stronger anticancer activity and can be taken on a daily basis.

International Publication No. 2008/136173 Japanese Patent No. 3548102 Japanese Patent No. 4077149 JP 2003-261444 A JP 2004-168749 A JP 2007-297304 A JP 2009-227609 A Japanese Patent No. 3934937 JP 2004-315386 A JP 2007-230946 A International Publication No. 2007/032551 International Publication No. 2007/091613 JP 2010-158223 A JP 2009-207492 A JP 2010-180167 A International Publication No. 2010/038842 JP 2009-201447 A Japanese Patent No. 435597 Japanese Patent No. 4336746 JP 2005-143377 A JP 2003-252784 A

Drug Discovery, 5,493-506 (2006) Science, 275 (10), 218-220 (1997) Journal of Dental Research, 84, 401-406 (2008)

  In view of the above-mentioned situation regarding resveratrol and caffeic acid, the present inventors have intensively studied to search for a novel physiological activity or a resveratrol derivative having a strong physiological activity and to establish a production method thereof. As a result, compared with resveratrol, caffeic acid, commercially available resveratrol derivatives, epigallocatechin gallate and luteolin, it is surprisingly safe and easy to heat-treat resveratrol and caffeic acid in the presence of a metal salt. The present invention has been completed by successfully producing a novel resveratrol derivative having excellent anticancer activity, particularly oral cancer activity, and α-glucosidase inhibitory activity.

Therefore, the present invention provides a novel resveratrol, caffeic acid, a commercially available resveratrol derivative, epigallocatechin gallate and luteolin having a stronger anticancer activity, an activity against oral cancer, and an α-glucosidase inhibitory activity. It is an object of the present invention to provide a veratrol derivative and to provide a method for efficiently and safely producing the novel resveratrol derivative.
The present invention also provides an anticancer agent, an α-glucosidase inhibitor, a sugar absorption inhibitor, a diabetes preventive agent, and a food, a pharmaceutical, and a quasi-drug characterized by containing the novel resveratrol derivative. For the purpose.

The gist of the present invention is as follows:
[1] Formula (1):

A novel resveratrol derivative represented by: or a pharmaceutically acceptable salt, ester or ether thereof,
[2] An anticancer agent comprising the novel resveratrol derivative according to [1], or a pharmaceutically acceptable salt, ester or ether thereof,
[3] An anticancer agent for oral cancer cells containing the novel resveratrol derivative according to [1], or a pharmaceutically acceptable salt, ester or ether thereof,
[4] α-glucosidase inhibitor containing the novel resveratrol derivative according to the above [1], or a pharmaceutically acceptable salt, ester or ether thereof,
[5] A sugar absorption inhibitor containing the novel resveratrol derivative according to the above [1], or a pharmaceutically acceptable salt, ester or ether thereof,
[6] Diabetes preventive agent containing the novel resveratrol derivative according to the above [1], or a pharmaceutically acceptable salt, ester or ether thereof,
[7] A novel resveratrol derivative according to the above [1], or a food, pharmaceutical or quasi-drug containing a pharmaceutically acceptable salt, ester or ether thereof,
[8] The novel resveratrol derivative according to the above [1], or a pharmaceutically acceptable salt thereof, wherein the target compound is produced by heat-treating resveratrol and caffeic acid in the presence of a metal salt. It relates to a process for the production of possible salts, esters or ethers.

The novel resveratrol derivative of the present invention, or a pharmaceutically acceptable salt, ester or ether thereof (hereinafter referred to as a novel resveratrol derivative) is resveratrol, caffeic acid, a commercially available resveratrol derivative, epigallo Compared to catechin gallate and luteolin, they are superior in anticancer activity and anti-oral cancer activity, and thus are useful as novel anticancer agents. Furthermore, since it also has α-glucosidase inhibitory activity, it is useful as a novel α-glucosidase inhibitor, sugar absorption inhibitor, and diabetes preventive agent.
Moreover, since the novel resveratrol derivative of this invention is excellent also in safety | security in addition to being excellent in the above physiological activities, it can be mix | blended with a foodstuff, a pharmaceutical, and a quasi-drug.

FIG. 1 shows the chromatogram obtained in Example 1. From the top, chromatogram before reaction, (1) chromatogram using mineral water as metal salt, (2) chromatogram using mineral premix, (3) chromatogram using magnesium phosphate trihydrate Shows gram. In the figure, the peak of A shows the novel resveratrol derivative of the present invention, and the peak of B shows the decomposition product of caffeic acid.

Hereinafter, the present invention will be described in detail.
The novel resveratrol derivative of the present invention has the formula (1):

Or a pharmaceutically acceptable salt, ester or ether thereof.

  In the novel resveratrol derivative, the carbon-carbon double bond may be trans or cis, and includes a mixture of a cis isomer and a trans isomer.

  Examples of the pharmaceutically acceptable salt of the novel resveratrol derivative include alkali metal salts such as lithium salt, sodium salt and potassium salt; alkaline earth metal salts such as magnesium salt, calcium salt and barium salt; aluminum Metal hydroxide salt such as aluminum hydroxide salt; alkylamine salt, dialkylamine salt, trialkylamine salt, alkylenediamine salt, cycloalkylamine salt, arylamine salt, aralkylamine salt, heterocyclic amine salt, etc. Amin salts; amino acid salts such as α-amino acid salts and ω-amino acid salts; peptide salts or primary, secondary, tertiary or quaternary amine salts derived therefrom. These pharmacologically acceptable salts can be used alone or in admixture of two or more.

  The pharmaceutically acceptable ether or ester of the novel resveratrol derivative refers to one in which one or more of the hydroxy groups (—OH) are etherified or esterified hydroxy groups. These etherified or esterified hydroxy groups are unsubstituted or substituted linear or branched alkyl groups having 1 to 26 carbon atoms, or unsubstituted or substituted 1 to 26 carbons. It may be derived from a linear or branched aliphatic, araliphatic or aromatic carboxylic acid having atoms. The etherified hydroxy group may further be a glycoside group, and the esterified hydroxy group may further be a glucuronide or sulfate group. These pharmacologically acceptable ethers or esters can be used alone or in admixture of two or more.

  The novel resveratrol derivative of the present invention having the structure as described above can be chemically synthesized according to a method well known in the art, but the reaction process is complicated and requires harmful reagents and processes. . In addition, chemical synthesis is complicated to remove impurities, and from the viewpoint of safety, it is necessary to thoroughly purify a novel resveratrol derivative, which is an industrially unsuitable method.

  Therefore, as a result of intensive studies, the present inventors conducted heat treatment of resveratrol and caffeic acid in the presence of a metal salt, without requiring harmful reagents and steps as in the chemical synthesis method described above, It has been found that a novel resveratrol derivative can be produced efficiently and safely. Below, the manufacturing method (henceforth the manufacturing method of this invention) of the novel resveratrol derivative | guide_body of this invention is demonstrated concretely.

In the production method of the present invention, resveratrol is used as a precursor. Resveratrol has structural isomers of trans form and cis form, but some conversion of trans form and cis form occurs by heating or ultraviolet rays. Therefore, resveratrol may be a trans isomer, a cis isomer, or a mixture of a trans isomer and a cis isomer. Resveratrol may be a naturally derived product extracted and purified from grape skin, or a chemically synthesized chemical product synthesized with high purity. When natural resveratrol is used, it does not need to be completely purified, and the desired production reaction proceeds as described later, and finally the novel resveratrol derivative of the present invention is obtained. Mixtures containing ingredients other than veratrol can also be used. Resveratrol also includes derivatives such as salts, ethers and esters, but these derivatives can also be used as raw materials in the production method of the present invention.
However, from the viewpoint of the recovery rate of the novel resveratrol derivative, a mixture containing 5% by weight or more in terms of resveratrol is desirable as a raw material.
As said resveratrol, you may use the extract from raw materials, such as grape peel and a peanut, a freeze-dried product, etc.

In the production method of the present invention, caffeic acid is also required as a precursor. Caffeic acid may be naturally derived or may be a chemically synthesized chemical product with high purity. When natural caffeic acid is used, it does not need to be completely purified, and the desired production reaction proceeds as will be described later, and finally the novel resveratrol derivative of the present invention is obtained. Mixtures containing other ingredients can also be used.
However, from the viewpoint of the recovered amount of the new resveratrol derivative, a mixture containing 5% by weight or more of caffeic acid is desirable as a raw material. Such raw materials include various fruits and juices, concentrated fruit juices, extracts of peels that are often discarded, or culture solutions containing caffeic acid by microbial fermentation as shown in the prior art or after enzyme reaction. Examples include caffeic acid-containing solutions.

In the production method of the present invention, resveratrol, caffeic acid, or a mixture of resveratrol and caffeic acid is dissolved in a suitable solvent. At this time, if the solvent is only water, the solubility of resveratrol and caffeic acid is remarkably low. Therefore, the solvent may be dissolved only in a mixed solution of water and an organic solvent or in an organic solvent. There is no restriction | limiting in particular in the compounding ratio of water and an organic solvent, and the kind of organic solvent, Resveratrol and caffeic acid should just fully melt | dissolve. Among them, it is preferable from the viewpoint of safety and cost to use a solvent containing only methanol or ethanol, or a mixed solution of water and methanol or water and ethanol. When using a post-reaction composition containing a new resveratrol derivative in foods without fully applying final purification, ethanol or hydrous ethanol may be used as a solvent for safety and legal reasons. desirable.
There is no limitation on the concentration of resveratrol and caffeic acid in the resulting solution containing resveratrol, caffeic acid, or a mixture of resveratrol and caffeic acid. Since the higher the respective concentrations, the smaller the amount of solvent used, and the like, there is an advantage that the concentration of resveratrol and caffeic acid is preferably close to the concentration at which resveratrol and caffeic acid are saturated with respect to each solvent.
Resveratrol and caffeic acid may not be completely dissolved in the solution before the formation reaction. For example, when a resveratrol-containing solution and a caffeic acid-containing solution are mixed, even if the resveratrol concentration and caffeic acid concentration in each solution are equal to or higher than the saturated concentration, Adjust it so that it is close.

  Next, it is preferable to adjust the pH of the solution containing resveratrol and caffeic acid (hereinafter referred to as resveratrol, caffeic acid-containing solution) to less than 8. As an adjustment method, for example, after preparing a solution containing resveratrol and caffeic acid, the pH may be adjusted by adding a pH adjusting agent, or the pH of the solvent may be adjusted in advance when preparing the solution. good. If the pH at the start of the reaction of the resveratrol / caffeic acid-containing solution is 8.0 or more, other reactions and decomposition of the target compound may occur on the other hand, resulting in a decrease in the final recovered amount of the new resveratrol derivative To do. Therefore, the pH at the start of the reaction is desirably 3 or more and less than 8.

In the production method of the present invention, a metal salt is added to the resveratrol and caffeic acid-containing solution. The metal salt may be any of an acid salt, a basic salt, and a normal salt, and may be any of a single salt, a double salt, and a complex salt. Furthermore, the metal salt may be one kind or a mixture of plural kinds. As an example of the metal salt, those approved as food additives are preferable in terms of safety. For example, magnesium salt, calcium salt, sodium salt, potassium salt, zinc salt, copper salt and the like that are permitted to be added to foods can be mentioned.
Moreover, as a mixture of the metal salts, for example, a mineral premix (Tanabe Seiyaku Co., Ltd., a mineral mixture mainly composed of zinc gluconate, ammonium iron citrate, calcium lactate, copper gluconate, and magnesium phosphate) In addition, substances containing several kinds of metal salts are listed. Moreover, mineral water can also be mentioned as a mixture containing a some metal salt.
In addition, as content of the said metal salt, what is necessary is just the quantity which can produce | generate a novel resveratrol derivative, and there is no limitation in particular.

  Next, the resveratrol and caffeic acid-containing solution are heat-treated in the presence of a metal salt. By this heat treatment, a formation reaction of a novel resveratrol derivative is performed. In order to efficiently promote the production reaction, it is preferable to adjust the heating temperature of the resveratrol and caffeic acid-containing solution to 110 ° C. or higher. Further, considering the boiling point of the solvent to be used, pressure heating is desirable. For example, resveratrol and caffeic acid-containing solution are put in an open container and the container is heated at a high temperature exceeding the boiling point of the solvent. Resveratrol and caffeic acid-containing solution are put in a sealed container and the container is heated. It is preferable to heat the solution so that the solution temperature reaches 110 ° C. or higher, for example, by heating under pressure using a retort device or an autoclave. From the viewpoint of recovery efficiency, it is more preferable that the solution temperature be 110 ° C. to 150 ° C. uniformly. The heating time is not limited as in the case of the heating temperature, and may be a time condition in which the target reaction efficiently proceeds. In particular, the heating time depends on the heating temperature, and it is desirable to set the heating time according to the heating temperature. For example, when heating near 130 ° C., a heating time of 5 minutes to 120 minutes is desirable. Further, the heating may be performed once or may be repeated repeatedly in a plurality of times. When heating in multiple steps, it is preferable to add a new solvent.

  The completion of the production reaction of the novel resveratrol derivative by the heat treatment may be judged by confirming the production amount of the novel resveratrol derivative by component analysis by HPLC, for example.

The resulting reaction solution contains the novel resveratrol derivative of the present invention.
In addition, when a new resveratrol derivative is produced by a process using only safe raw materials, it can be used in foods, pharmaceuticals or quasi drugs in the state of a mixture containing the new resveratrol derivative. is there. For example, when a naturally occurring resveratrol or caffeic acid is dissolved in a water-containing ethanol solvent and heated with mineral water or mineral premix, the resulting reaction solution may be used as one of the food ingredients. Is possible.

  Also, if you want to improve the flavor and further enhance the functionality, concentrate the reaction solution to increase the concentration of the new resveratrol derivative, or purify the reaction solution to obtain a pure product of the new resveratrol derivative. Can be obtained. Concentration and purification can be performed by a known method. For example, the novel resveratrol derivative can be concentrated by extraction with a solvent extraction method such as chloroform, ethyl acetate, ethanol, methanol or the like or a supercritical extraction method with carbon dioxide gas. It is also possible to perform concentration and purification using column chromatography. A membrane treatment method such as a recrystallization method or an ultrafiltration membrane can also be applied.

  In addition, when the novel resveratrol derivative represented by the formula (1) is separated and recovered from the reaction solution, column chromatography, HPLC, or the like may be used.

  A powdered novel resveratrol derivative can be obtained by removing the solvent from the concentrate or purified product by drying under reduced pressure or lyophilization, if necessary.

  In addition, the obtained new resveratrol derivative may be converted into a salt of the new resveratrol derivative, or the etherified or esterified hydroxy group of the new resveratrol derivative, if necessary, by a method known in the art. Also good.

  The novel resveratrol derivative of the present invention obtained as described above has extremely superior anticancer activity compared to resveratrol, caffeic acid, commercially available resveratrol derivatives, epigallocatechin gallate and luterion. Furthermore, it has α-glucosidase inhibitory activity. Accordingly, it is possible to provide an anticancer agent, α-glucosidase inhibitor, sugar absorption inhibitor or diabetes preventive agent containing a novel resveratrol derivative as an active ingredient.

  In addition, the further effect efficacy which the novel resveratrol derivative | guide_body obtained by this invention has can be used in the range which can be estimated from the obtained physiological activity data.

  Since the safety of resveratrol and caffeic acid as raw materials has been confirmed, it is considered that the safety of the novel resveratrol derivative of the present invention is also excellent.

  Moreover, since the novel resveratrol derivative of the present invention exhibits the physiological activity as described above, it can be used by blending it with foods, pharmaceuticals, quasi drugs and the like.

  The food may be in any form such as beverage, alcoholic beverage, jelly, confectionery, etc., and among confectionery, hard candy, soft candy, gummy candy, tablet that is excellent in storage and carrying due to its capacity etc. There are no particular limitations. Further, by adding a novel resveratrol derivative to wine, it is possible to obtain a new wine that further enhances the health function effect of the wine. Like this new wine, food and drink with both palatability and health function effects is a field with very high social needs and can respond to this. In addition, since the novel resveratrol derivative has excellent anticancer activity against cancer, particularly oral cancer, as described later, a candy that can be easily ingested for the purpose of preventing oral cancer that is currently a problem, It is also useful as a gummy candy or tablet. Furthermore, since the novel resveratrol derivative has α-glucosidase inhibitory activity as will be described later, it can be easily ingested for the purpose of preventing diseases such as diabetes that are currently a problem, gummy candy, tablet Etc. are also useful. The food includes functional food, health food, health-oriented food, and the like.

  Examples of the pharmaceutical include solid preparations such as powders, tablets, pills, capsules, fine granules and granules, liquids such as liquids, suspensions and emulsions, gels and the like. If necessary, the granules of capsules containing tablets, pills, granules, granules can be sugar-coated with sugars such as sucrose, sugar alcohols such as maltitol, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose, etc. It can also be coated. Alternatively, it may be covered with a film of gastric or enteric material. Moreover, in order to improve the solubility of a formulation, a well-known solubilization process can also be performed. Based on a conventional method, it may be used in an injection or a drip.

  Examples of quasi drugs include quasi drugs used in the oral cavity, such as toothpaste, mouthwash, and mouth rinse.

When preparing foods, pharmaceuticals or quasi drugs using the novel resveratrol derivative of the present invention, the components usually used in foods, drugs or quasi drugs are appropriately selected within the range that does not impair the effects of the present invention. It can mix | blend arbitrarily.
For example, in the case of food, food such as water, alcohol, starch chamber, protein, fiber, sugar, lipid, vitamin, mineral, flavoring, coloring, sweetener, seasoning, stabilizer, preservative Can be combined with raw materials or materials usually blended in
In the case of quasi-drugs, combinations of main ingredients, base materials, surfactants, foaming agents, wetting agents, thickeners, clearing agents, flavoring agents, coloring agents, stabilizers, preservatives, bactericides, etc. Based on the law, it can be made into a liquid, ointment-like or sprayable final form.
In particular, considering the field of physiological activity of the novel resveratrol derivative of the present invention, it is preferably used in the field of health maintenance and promotion such as prevention and treatment of cardiovascular diseases such as cancer and hypertension, and further in the field of disease healing.

  When the novel resveratrol derivative of the present invention is added to food, it is usually preferable to add 0.001 to 20% by weight based on the food.

  When the novel resveratrol derivative of the present invention is used for pharmaceutical purposes, for example, the amount of intake thereof is not particularly limited as long as the desired improvement, treatment or prevention effect is obtained. It is appropriately selected according to the age, sex, constitution and other conditions, the type and degree of disease. The intake is preferably about 0.1 mg to 1,000 mg per day, which can be divided into 1 to 4 times a day.

  When the novel resveratrol derivative of the present invention is added to a quasi drug, it is usually preferable to add 0.001 to 30% by weight in the quasi drug.

  Further, since the novel resveratrol derivative of the present invention is excellent in safety, not only for humans, for example, non-human animals such as rats, mice, guinea pigs, rabbits, sheep, pigs, You may mix | blend with mammals, such as a cow, a horse, a cat, a dog, a monkey, a chimpanzee, birds, amphibians, a reptile, etc., or a feed. As feed, for example, livestock feed used for sheep, pigs, cattle, horses, chickens, etc., feed for small animals used for rabbits, rats, mice, etc. The pet food used for a cat, a small bird, a squirrel, etc. is mentioned.

  EXAMPLES Next, although this invention is demonstrated in detail based on an Example, this invention is not limited only to this Example.

(Example 1: Examination of production method of novel resveratrol derivative)
100 mg of trans-resveratrol (manufactured by Tokyo Chemical Industry Co., Ltd.) and 100 mg of caffeic acid (manufactured by Wako Pure Chemical Industries, Ltd.) are dissolved in 2 mL of ethanol, and (1) mineral water (trade name “Gerol Steiner” Sapporo Beverage ( Co., Ltd.) 2 mL, (2) mineral premix 100 mg, water 2 mL, (3) magnesium phosphate trihydrate (manufactured by Wako Pure Chemical Industries, Ltd., main component of mineral premix) 100 mg, water 2 mL In addition, 3 types of resveratrol and caffeic acid-containing solutions (pH: (1) 5.1, (2) 4.7, (3) 5.0) were prepared. These resveratrol and caffeic acid-containing solutions were heated at 130 ° C. for 30 minutes in an autoclave (manufactured by Sanyo Electric Co., Ltd., “SANYO LABO AUTOCLAVE”). 1 mL of the obtained reaction solution was diluted to 50 mL with methanol, and 10 μL of this was analyzed by HPLC.

HPLC analysis was performed under the following conditions.
Column: Column for reverse phase “Develosil (registered trademark) C-30-UG-5” (4.6 mm.d. × 250 mm)
Mobile phase: A: H ₂ O (0.1% trifluoroacetic acid (TFA)), B: Acetonitrile (0.1% TFA)
Flow rate: 1 mL / min
Injection: 10 μL
Detection: 254 nm
Gradient (% by volume): 30 minutes from 80% A / 20% B to 20% A / 80% B, 5 minutes from 20% A / 80% B to 100% B, 10 minutes at 100% B (all linear)

The obtained chromatogram is shown in FIG. From the top, the chromatograms of the reaction solutions (1), (2), and (3) are shown before the reaction. After the reaction, peaks other than resveratrol and caffeic acid were detected, confirming that a plurality of compounds were produced.
For example, in the figure, the peak of B is a decomposition product of caffeic acid, and other than that, there was a significant difference in the amount of production before and after the reaction, the peak of A being a new resveratrol derivative described later. is there. In addition, there is almost no difference in the amount of peak component A generated between the reaction solutions (1), (2), and (3), that is, the production of a novel resveratrol derivative depending on the type of metal salt used this time. The difference in quantity was small.

(Example 2: Mass production of novel resveratrol derivative)
1 g of trans-resveratrol and 1 g of caffeic acid were dissolved in 20 mL of ethanol, and 20 mL of mineral water was added to obtain resveratrol and a caffeic acid-containing solution (pH = 5.1). This resveratrol and caffeic acid-containing solution was heated in an autoclave at 130 ° C. for 90 minutes. 1 mL of the obtained reaction solution was made up to 50 mL with methanol and analyzed by HPLC in the same manner as in Example 1, and the same chromatogram as in Example 1 was confirmed.

(Example 3: Isolation and structure determination of a novel resveratrol derivative)
Of the reaction product obtained in Example 2, the compound contained in the peak shown in FIG. 1A was isolated by preparative HPLC and dried by a conventional method to obtain 80.6 mg of a new compound (hereinafter referred to as UHA1027). . The isolated and purified UHA1027 became a brown powdery substance.

Next, the molecular weight of UHA1027 was measured by high-resolution electron ionization-mass spectrometry, and the measured value was 364.3917. The following molecular formula was obtained from comparison with the theoretical value.
Theoretical value C22H20O5 (M ⁺ ): 364.3912
Molecular formula C ₂₂ H ₂₀ O ₅

  Next, the UHA1027 is subjected to nuclear magnetic resonance (NMR) measurement, and it is confirmed from analysis of 1H-NMR, 13C-NMR and various two-dimensional NMR data that the UHA1027 has a structure represented by the formula (1). did. It was shown that the novel resveratrol derivative represented by the formula (1) can be efficiently produced by the method of the present invention.

  For NMR measurements, UHA1027

Table 1 shows the ¹ H nuclear magnetic resonance spectrum and ¹³ C nuclear magnetic resonance spectrum.
The values were δ and ppm, and the solvent was measured with methanol-d ₃ .

Moreover, the physicochemical properties of UHA1027 were as follows.
(Properties)
Brown powder (soluble)
Water: Slightly soluble methanol: Dissolved ethanol: Dissolved DMSO: Dissolved chloroform: Dissolved ethyl acetate: Dissolved

(Example 4: Anticancer effect of UHA1027 on human myeloid leukemia cells)
Next, in order to see the effect of each compound on cancer cells, the cancer cell proliferation inhibitory action using HL-60 cells (Human proneolytic leukemia cells: human myeloid leukemia cells) was tested.

For the culture of HL-60 cells, a high nutrient medium RPMI-1690 (manufactured by SIGMA) containing 4 mM glutamine (manufactured by L-Glutamine SIGMA), 10% fetal bovine serum (FBS Biological industries). used. A 96-well plate for cell culture (manufactured by Corning) was used for the test, and 100 μL per well of HL-60 cells adjusted to have a cell number of 5 × 10 ⁵ cells / mL was seeded and used for the test. .

Four kinds of samples were used: resveratrol, caffeic acid, epigallocatechin gallate (EGCg, manufactured by Wako Pure Chemical Industries, Ltd.) which is a natural product having anticancer activity, and UHA1027 which is a product of the present invention. In the sample preparation, each compound was dissolved in dimethyl sulfoxide (DMSO, manufactured by Wako Pure Chemical Industries, Ltd.), and the final concentrations in the HL-60 cell culture solution were 6.3 μM, 12.5 μM, The test was started under the culture conditions of 37 ° C. and 5% CO ₂ by adding 25 μM, 50 μM, and 100 μM.

The number of viable cells was quantified by the MTT method using Cell counting kit-8 (manufactured by DOJINDO). That is, 24 hours after the start of the test, 10 μL of the Cell counting kit-8 solution was added to each well and stirred well. The light-shielding reaction was performed for 1 hour at 37 ° C. and 5% CO ₂ . Thereafter, absorbance at a measurement wavelength of 450 nm was measured using a plate reader (“BIO-RAD Model 680”, manufactured by Bio-Rad Laboratories), and the cell viability was calculated based on the obtained data. The cell viability is a value calculated by setting the number of viable cells in a culture solution to which only DMSO as a solvent is added as 100% and the number of viable cells in each compound concentration as a relative value. From the relationship between the concentration of each compound and the cell viability, a concentration IC ₅₀ (half maximum inhibitory concentration: 50% inhibitory concentration) that suppresses cell proliferation by 50% was calculated (Table 2). From these results, UHA1027 was found to have a strong ability to suppress cancer cell growth. This effect was not observed at all for caffeic acid, and more active than resveratrol and EGCg. Therefore, the high significance of converting resveratrol and caffeic acid into novel resveratrol derivatives was demonstrated.

(Example 5: Anticancer effect of UHA1027 on human oral cancer cells)
Next, in order to see the effect of each compound on cancer cells, the cancer cell proliferation inhibitory action using SCC-4 cells (human tongue squamous cell carcinoma cells, manufactured by ATCC) was tested.

For culturing SCC-4 cells, 400 ng / mL hydrocortisone (Hydrocortisone, manufactured by Sigma-Aldrich Japan), 1% antibiotic-antimycotic (manufactured by Antibiotic-Antilytic, Gibco (GIBCO)), 10% FBS DMEM / F-12 (1: 1) medium (Gibco) containing (ATCC) was used. For the test, a collagen I-coated 96-well plate for cell culture (manufactured by BD Japan) was used, and 100 μL of SCC-4 cells adjusted to have a cell number of 5 × 10 ⁵ cells / mL were seeded per well. This was cultured for 24 hours under conditions of 37 ° C. and 5% CO ₂ , and used for testing in a state of 80% confluence or higher.

Samples are resveratrol and caffeic acid, luteolin (manufactured by Wako Pure Chemical Industries, Ltd.), a natural product having anticancer activity against SCC-4 cells, and resveratrol derivative ε-viniferin (Wako Pure Chemical Industries, Ltd.). And 5 types of UHA1027 which is the product of the present invention. Samples were prepared by dissolving each compound in DMSO to 0.63 mM, 1.25 mM, 2.5 mM, 5 mM, and 10 mM. This was added so that the final concentrations in the SCC-4 cell culture medium were 6.3 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM, respectively, and the test was started under 37 ° C. and 5% CO ₂ culture conditions. . A negative control was prepared by adding the same amount of DMSO as a solvent.

The number of viable cells was quantified by the MTT method using “Cell counting kit-8”. That is, 48 hours after the start of the test, 10 μL of the Cell counting kit-8 solution was added to each well and well stirred. After a light-shielding reaction at 37 ° C. and 5% CO ₂ for 1 hour, the absorbance at a measurement wavelength of 450 nm was measured using a plate reader, and the cell viability was calculated based on the obtained data. The cell viability is a value calculated by setting the number of viable cells in a culture solution to which only DMSO as a solvent is added as 100% and the number of viable cells in each compound concentration as a relative value. From the relationship between the concentration of each compound and the cell viability, the concentration IC ₅₀ that suppresses cell proliferation by 50% was calculated (Table 3). From these results, UHA1027 was found to have a strong ability to suppress the growth of oral cancer cells. This effect was not observed in resveratrol and caffeic acid at all, and further showed higher activity than luteolin and ε-biniferin. Therefore, the high significance of converting resveratrol and caffeic acid into novel resveratrol derivatives was shown.

(Example 6: α-glucosidase inhibitory action of UHA1027)
Next, the inhibitory action of UHA1027 on α-glucosidase was evaluated.

Three types of samples were used: resveratrol, caffeic acid, and UHA1027 which is the product of the present invention. As a method, a kit “Quantich ^™ α-Glucosidase Assay Kit” (manufactured by Bioassay Systems) was used, and an optimized method was used with reference to the method in its instruction manual. That is, each compound was prepared in DMSO to be 1 mM, 5 mM, and 10 mM, and this was further adjusted to 100 μM, 500 μM, and 1000 μM with 100 mM sodium phosphate (NaH ₂ PO ₄ , Na ₂ HPO ₄ , The sample solution was diluted with a buffer solution (pH 6.5) manufactured by Wako Pure Chemical Industries, Ltd. Next, yeast-derived α-glucosidase (manufactured by SIGMA) was adjusted to 2.5 U / mL with a sodium phosphate buffer (pH 6.5) to obtain an enzyme solution. Further, 4 μL of p-nitrophenyl-α-D-glucopyranoside (α-NPG) was added to 100 μL of the assay buffer attached to the kit, and this was used as a working buffer. 10 μL of sample solution, 10 μL of enzyme solution, and 80 μL of working buffer were mixed on a 96-well microplate (manufactured by ASONE Co., Ltd.) (sample final concentrations 10 μL, 50 μL, 100 μL, final enzyme concentration 0.25 U / mL). A control prepared in the same manner using DMSO was used as a control. Absorbance measurement at a measurement wavelength of 415 nm was performed using a plate reader at the start of the reaction of the enzyme reaction solution (0 minutes) and after the reaction (10 minutes). From the numerical values obtained here, the inhibition rate was calculated using the following formula.

Inhibition rate (%) = 100 − {(ST ₀ −ST ₁₀ ) / (CT ₀ −CT ₁₀ ) × 100}
ST ₀ : Compound reaction 0 min
ST ₁₀ : Compound reaction 10 minutes
CT ₀ : DMSO reaction 0 min
CT _10: DMSO reaction 10 minutes

The concentration IC ₅₀ that inhibits the enzyme reaction by 50% was calculated from the inhibition rate at each concentration obtained. This is shown in Table 4.

  As a result, UHA1027 was found to have an α-glucosidase inhibitory effect. This action is not observed in caffeic acid, and the α-glucosidase inhibitory activity of UHA1027 is higher than that of resveratrol. Therefore, it is highly significant that resveratrol and caffeic acid are converted into novel resveratrol derivatives. It has been shown.

(Example 7: Difference in production amount of UHA1027 depending on heating temperature)
A mixed solution (pH = 5.1) of resveratrol 100 mg, caffeic acid 100 mg, ethanol 2 mL, and mineral water 2 mL was heated in an autoclave at 70 ° C., 90 ° C., 110 ° C., and 130 ° C. for 20 minutes. . 1 mL of the post-reaction composition obtained under each temperature condition was diluted to 50 mL with methanol and analyzed by HPLC in the same manner as in Example 1.

  As a result, the formation of UHA1027 was confirmed at 110 ° C. or higher. The production ratio (% by weight) from the total amount of resveratrol and caffeic acid is 70 ° C., 90 ° C. is not produced, 110 ° C. is extremely small, 130 ° C. is 4%, and heating at 130 ° C. is the most, and UHA1027 Was generated.

(Example 8: Preparation of UHA1027-containing extract)
A mixed solution prepared by adding 10 g of grape skin extract powder (resveratrol raw material), 10 g of kiwifruit juice concentrate, 10 mL of ethanol, and 10 mL of mineral water was heated at 130 ° C. for 90 minutes in an autoclave. The obtained reaction solution was heated under reduced pressure to dryness to obtain 14 g of UHA1027-containing extract. When 14 g of the obtained UHA1027 extract was confirmed by the same method as in Example 3, 0.056 g of UHA1027 was contained. This work was repeated as necessary.

(Example 9: Food containing UHA1027)
1 g of UHA1027-containing extract obtained in Example 8 was previously dissolved in 100 mL of ethanol, and this was composed of 500 g of paratinite (manufactured by Paratinit) and 714 g of reduced maltose starch syrup (manufactured by Towa Kasei Kogyo Co., Ltd., Bx70) (500 g of solid content). The sugar solution was mixed in a vacuum kettle and cooked to 155 ° C. under a vacuum degree of −600 mmHg. This was put in a cooling plate, and at about 100 ° C., 15 g of citric acid, 1.1 mL of lemon flavor, and 1 mL of pigment were added, and solidified after mixing to obtain a non-sugar hard candy. This non-sugar hard candy is not only easy to eat as a confectionery, but it can also be taken regularly to reduce the risk of cancer spread in cancer patients, and to reduce the risk of cancer development in healthy individuals. It can also be used as a functional food that is expected to prevent cancer. Furthermore, it can be used as a functional food that is expected to prevent a rapid increase in blood glucose level due to the sugar absorption inhibitory action in diabetic patients and the reserve group.

(Example 10: Drug containing UHA1027)
UHA1027 obtained by the same method as in Examples 2 and 3 was dissolved in ethanol, added to microcrystalline cellulose and adsorbed, and then dried under reduced pressure. Using this adsorbent, a tableted product was obtained according to a conventional method. The formulation is 10 parts by weight of UHA1027, 23 parts by weight of corn starch, 12 parts by weight of lactose, 8 parts by weight of carboxymethylcellulose, 32 parts by weight of microcrystalline cellulose, 4 parts by weight of polyvinylpyrrolidone, 3 parts by weight of magnesium stearate, 8 parts by weight of talc. Street. This tableted product can be effectively used as a medicine for the purpose of healing cancer and diabetes.

(Example 11: Quasi-drug containing UHA1027)
1.2 g of UHA1027 obtained by the methods of Examples 2 and 3 was dissolved in 10 mL of ethanol, and 20 g of taurine, 0.12 g of vitamin B1 nitrate, 0.6 g of sodium benzoate, 4 g of citric acid, and 10 g of polyvinylpyrrolidone were all purified water. And made up to 1000 mL. The pH was adjusted to 3.2 using dilute hydrochloric acid. 50 ml of 1000 ml of the obtained solution was filled in a glass bottle and sterilized at 80 ° C. for 30 minutes to complete a quasi-drug drink. In addition to the purpose of nutritional supplementation, this drink reduces the risk of cancer spread in cancer patients, reduces the risk of developing cancer, prevents cancer, and causes rapid blood glucose levels in diabetics and their preparatory groups. It can be effectively used as a quasi-drug intended to reduce the increase in value.

Claims (8)

A novel resveratrol derivative represented by the following formula (1), or a pharmaceutically acceptable salt, ester or ether thereof.

  An anticancer agent comprising the novel resveratrol derivative according to claim 1, or a pharmaceutically acceptable salt, ester or ether thereof.   An anticancer agent for oral cancer cells containing the novel resveratrol derivative according to claim 1, or a pharmaceutically acceptable salt, ester or ether thereof.   An α-glucosidase inhibitor comprising the novel resveratrol derivative according to claim 1, or a pharmaceutically acceptable salt, ester or ether thereof.   A sugar absorption inhibitor comprising the novel resveratrol derivative according to claim 1, or a pharmaceutically acceptable salt, ester or ether thereof.   An antidiabetic agent comprising the novel resveratrol derivative according to claim 1, or a pharmaceutically acceptable salt, ester or ether thereof.   A food, pharmaceutical product or quasi-drug containing the novel resveratrol derivative according to claim 1, or a pharmaceutically acceptable salt, ester or ether thereof.   The novel resveratrol derivative according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the target compound is produced by heat-treating resveratrol and caffeic acid in the presence of a metal salt, Method for producing ester or ether.

Images